- Centers & Specialties
- Clinical Interests
- Diabetes management
- Intensive therapies of diabetes
- Medical Education
- MD, Mount Sinai School of Medicine
- Residency, Brigham and Women's Hospital
- Fellowship, Massachusetts General Hospital
- Board Certifications
- Internal Medicine
- Diabetes & Metabolism
- Foreign Languages
- Boston: Massachusetts General Hospital
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- Cigna (PAL #'s)
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - other
- Harvard Pilgrim Health Plan - PBO
- Harvard Pilgrim Health Plan - SSN
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- Neighborhood Health Plan - ACD
- Neighborhood Health Plan - PBO
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Railroad Medicare - ACD
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - PBO
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
Following the cutting of a ceremonial blue ribbon and an enthusiastic round of applause, the doors to the new MGH Translational and Clinical Research Center (TCRC) officially opened Nov. 30.
Her Highness Sheikha Moza Bint Nasser of Qatar visited the MGH May 19 for a special presentation about type 1 diabetes treatment and research, islet and whole organ transplantation and the future of a bionic pancreas.
At this year’s annual Community Health Day, more than 70 guests gathered at the MGH Revere HealthCare Center to celebrate local community health efforts and learn about one of today’s most pressing health topics: diabetes.
Intensive lifestyle changes aimed at modest weight loss reduced the rate of developing type 2 diabetes by 34 percent compared with placebo in people at high risk for the disease, researchers conclude based on 10 years of data.
Near-normal control of glucose beginning as soon as possible after diagnosis would greatly improve the long-term prognosis of type 1 diabetes, concludes a study published in the July 27, 2009, issue of the Archives of Internal Medicine, which updates information about the clinical course of type 1 diabetes.
quotes MGH physician David Nathan
50 Staniford Street
Boston, MA 02114-2517